Table 2 Treatment characteristics
From: IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial
R2: visible residual tumor | R1: R1/ Pn + resected tumors | total | |
|---|---|---|---|
Patient number | 16 | 13 | 29 |
Median dose (GyE/ Gy) | 74.5 | 74.2 | 74.2 |
C12 | 23.81 | 23.87 | 23.83 |
IMRT | 50.74 | 50.42 | 50.6 |
C12 optimization technique | |||
IMPT (pts) | 11 | 9 | 20 |
SBO (pts) | 5 | 4 | 9 |
IMRT technique | |||
step& shoot IMRT | 10 | 12 | 22 |
Tomotherapy | 6 | 1 | 7 |
Treatment volumes (ml) | |||
CTV1 | 167.1 | 94.13 | 138.38 |
CTV1 range | 161.95 - 618.5 | 48.66 - 187.82 | 32.56 - 390.6 |
CTV2 | 466.73 | 413.2 | 431.5 |
CTV2 range | 190.13 - 922.71 | 32.56 - 390.6 | 161.9 - 922.7 |
Bilateral level II/III (pts) | 6 | 2 | 8 |